

AN EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF PHENYTOIN SODIUM

Field of the Invention

The present invention relates to an extended release pharmaceutical composition of
5 phenytoin sodium comprising a blend of phenytoin sodium and hydrophilic polymer(s).
Also provided is a process for preparing the extended release pharmaceutical composition.

Background of the Invention

Phenytoin sodium is a known antiepileptic compound. Phenytoin, its sodium salt,
and procedures for its manufacture are well known and disclosed in, for example, Kao et
10 al., U.S. Patent No. 4,696,814; Fawzi et. Al., U.S. Patent No. 4,642,316 and Henze et al.,
U.S. Patent No. 2,409,754, all of which are incorporated herein by reference.

Phenytoin sodium is commercially available as 30 mg and 100 mg capsules
marketed by Parke Davis, sold under the brand name Dilantin®. These capsules contain
lactose, confectioner's sugar, talc, magnesium stearate and phenytoin sodium as loose
15 powder. The capsules are sealed with a band. Drug release problems associated with
these pharmaceutical compositions have resulted in numerous recalls for failure to meet
dissolution requirements. Moreover, Dilantin® requires multiple, repetitive dosing
intervals. A dose of 100 mg of Dilantin requires a capsule size #3 (230 mg), therefore in
order to incorporate a greater dose of the drug using Dilantin capsules to make, for
20 example, an extended release dosage form, the size of the capsules would also have to be
increased which, with respect to patient compliance, is not desirable.

Extended release oral capsules containing 200 mg and 300 mg phenytoin sodium
are also available commercially under the brand name Phenytek®. These capsules contain
phenytoin sodium in an erodible matrix that includes povidone, hydroxyethyl cellulose,
25 microcrystalline cellulose, magnesium oxide, colloidal silicon dioxide and magnesium
stearate as described in Mylan's U.S. Patent No. 6,274,168 and its continuation-in-part
U.S. Patent No. 6,620,432 (prior publication: U.S. 20010043945). These extended
release, oral capsules are prepared by mixing phenytoin sodium with diluents, binder(s),
alkaline pH modifier(s), or a combination thereof, and then granulating with an aqueous
30 solvent, which may or may not contain a binder(s). The dried granules are milled and
finally blended with other excipients. The blend is filled into capsules or compressed into
tablets. The tablets then may be additionally coated and/or filled into capsules. The

pharmaceutical compositions as described by these patents are in the form of granules or tablets, which thus require the additional steps of granulation or compression, respectively.

Summary of the Invention

In one general aspect there is provided an extended release pharmaceutical
5 composition includes a blend of phenytoin sodium and one or more hydrophilic polymers. The blend forms a matrix after contacting an aqueous media and the matrix retains at least about 20% of the phenytoin after 1 hour.

Embodiments of the pharmaceutical composition may include one or more of the following features. For example, the composition may contain a blend of the phenytoin
10 sodium and the hydrophilic polymers in a powder form with about 40 percent to about 70 percent by weight of the phenytoin sodium. The blend may contain about 10 percent to 30 percent by weight of the one or more hydrophilic polymers

The hydrophilic polymers may be one or more of carbohydrate gum, cellulose ether, acrylic acid polymer, and mixtures thereof. The carbohydrate gum may include one
15 or more of xanthan gum, tragaçanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, and mixtures thereof. Particularly, the carbohydrate gum may be xanthan gum.

The cellulose ethers may be one or more of methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl butyl
20 cellulose, carboxymethyl cellulose, and combinations thereof. Particularly, the cellulose ether may be hydroxypropyl cellulose. In another embodiment the cellulose ether may be hydroxypropyl methylcellulose. The acrylic acid polymers may be carboxy vinyl polymer. The hydrophilic polymers may be a combination of a cellulose ether and carbohydrate gum. In one embodiment, the cellulose ether may be a combination of
25 hydroxypropyl cellulose and hydroxypropyl methylcellulose and the carbohydrate gum may be xanthan gum.

The pharmaceutical composition may optionally include pharmaceutically acceptable excipients. The pharmaceutically acceptable excipients may be one or more of diluents, lubricants and glidants.

30 The diluents may be one or more of microcrystalline cellulose, powdered cellulose, lactose, starch, mannitol, calcium hydrogen phosphate, and dextrose. In one embodiment the diluent may be microcrystalline cellulose.

The lubricants may be one or more of talc, magnesium stearate, calcium stearate, stearic acid, hydrogenated vegetable oil, polyethylene glycol, sodium stearyl fumarate and sodium benzoate. In one embodiment the lubricant may be magnesium stearate. In another embodiment the lubricant may be talc.

- 5 The glidants may be one or both of colloidal silicon dioxide and talc. In one embodiment the glidant may be silicon dioxide.

- The pharmaceutical composition may have an in vitro dissolution profile when tested using USP Apparatus I in water at 75 rpm of a) not more than about 35 percent released in about 30 minutes, b) between about 30 percent and about 75 percent released
10 in about 60 minutes, and c) not less than about 65 percent released in about 120 minutes.

In another general aspect there is provided a process for preparing an extended release pharmaceutical composition that includes a blend of phenytoin sodium and one or more hydrophilic polymers. The process includes blending phenytoin sodium and one or more hydrophilic polymers, screening the blend, and filling the blend into capsules.

- 15 The matrix formed from the pharmaceutical composition may retain at least about 30% of phenytoin after 1 hour. In another embodiment the matrix may retain at least about 60% of phenytoin after 1 hour.

- The process includes a blend of phenytoin sodium and hydrophilic polymers and may be filled into the capsule in the form of a powder. This pharmaceutical composition
20 may include about 40 percent to about 70 percent by weight of phenytoin sodium. The pharmaceutical composition also may include from about 10 percent to about 70 percent by weight of the one or more hydrophilic polymers. The hydrophilic polymers may be one or more of carbohydrate gum, cellulose ether, acrylic acid polymer, and mixtures thereof.

- 25 The carbohydrate gum may be one or more of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia, gellan gum, locust bean gum, and mixtures thereof. In one embodiment the carbohydrate gum may be xanthan gum.

- The cellulose ethers may be one or more of methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, hydroxypropyl butyl
30 cellulose, carboxymethyl cellulose, and combinations thereof. In one embodiment the cellulose ether may be hydroxypropyl cellulose. In another embodiment the cellulose

ether may be hydroxypropyl cellulose. The acrylic acid polymer may be carboxy vinyl polymer.

In one embodiment one or more hydrophilic polymers may include a combination of a cellulose ether and a carbohydrate gum. The cellulose ether may be a combination of
5 hydroxypropyl cellulose and hydroxypropyl methylcellulose and the carbohydrate gum may be xanthan gum.

The mixture may be blended with one or more pharmaceutically acceptable excipients and with the phenytoin sodium and the one or more hydrophilic polymers.

The pharmaceutically acceptable excipients may be one or more of diluents,
10 lubricants, and glidants.

The pharmaceutical composition made by this process may have the following in vitro dissolution profile when tested using USP Apparatus I in water at 75 rpm: a) not more than about 35 percent released in about 30 minutes, b) between about 30 and about 75 percent released in about 60 minutes and c) not less than about 65 percent released in
15 about 120 minutes.

In another general aspect there is provided a method for controlling or treating one or more of generalized tonic-clonic (grand mal) seizures and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery in a patient in need thereof. The method includes
20 administering an extended-release pharmaceutical composition which includes a blend of phenytoin sodium and one or more hydrophilic polymers. The blend forms a matrix after contacting an aqueous media and the matrix retains at least about 20% of the phenytoin after 1 hour.

Embodiments of the method may contain any one or more of the features described
25 above and one or more of the following features. For example, the pharmaceutical composition described above may also be administered with an additional pharmaceutically active agent. The additional pharmaceutically active agent may be one or both of phenobarbitone and pentobarbital.

The details of one or more embodiments of the inventions are set forth in the
30 description below. Other features, objects and advantages of the inventions will be apparent from the description and claims.

Detailed Description

The inventors have discovered that it is possible to prepare extended release pharmaceutical compositions without performing granulation and compression, and yet achieve batch-to-batch reproducible dissolution profiles. To accomplish this result, the
5 inventors have formulated extended-release capsules by employing a simple process that advantageously does not involve the extra steps of granulating, drying, milling, compressing, and band-sealing after filling in capsules. This reduction in process steps likewise reduces the manufacturing costs of the dosage form. One aspect of this savings results from using a powder to fill the capsules rather than using a granulation to fill the
10 capsules. Surprisingly, these benefits are attained while still maintaining generally reproducible extended-release properties.

Powders generally require no further treatment prior to their use and present few complicating factors when compared to granules or tablets. The main drawback of filling
15 powders into capsules is the resulting non-reproducible in vitro release profiles. The inventors have discovered that the drug release can be regulated, and batch-to-batch variation can be minimized, by mixing or blending the active ingredient with one or more hydrophilic polymers and then filling the mixture or blend into capsules.

Phenytoin sodium is a monosodium salt of 5,5-diphenyl hydantoinate and is described on page 1259 of the Twelfth Edition of the Merck Index, which is incorporated
20 herein by reference. It is useful as an anticonvulsant, for the treatment of generalized tonic-clonic (grand mal) seizures in adults and children, and in the treatment of simple and complex partial seizures.

Phenytoin sodium used in accordance with the present invention includes between about 40% to about 70% w/w of the total formulation weight.

25 Suitable pharmaceutically acceptable hydrophilic polymers used in the present pharmaceutical composition may include one or more of the carbohydrate gums, cellulose ethers, acrylic acid polymers and mixtures thereof.

Suitable carbohydrate gums may be selected from one or more of xanthan gum, tragacanth gum, gum karaya, guar gum, acacia gellan gum, locust bean gum and the like.
30 Upon contact with the gastrointestinal fluid, the gums form a viscous gel and sustain the release of the drug even when used in very small amounts.

Suitable cellulose ethers used in accordance with the present pharmaceutical composition include one or more of methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl ethyl cellulose and hydroxypropyl butyl cellulose.

5 Suitable acrylic acid polymers include carboxyvinyl polymers such as those available under the brand name Carbopol (B.F. Goodrich, USA).

10 The one or more hydrophilic polymers may be present in an amount from about 10% to about 30% w/w of the composition. The use of small amounts of hydrophilic polymers ensures a low total weight of the dosage form and therefore provides the therapeutic dosage of the drug in a single unit as compared to two or three units which need to be administered when using the commercially available Dilantin® 100 mg capsules. The present invention provides obvious benefits with respect to better patient convenience and therefore better patient compliance.

15 In addition to the active ingredient and one or more hydrophilic polymers, the composition may optionally contain one or more pharmaceutically acceptable excipients, including colorants, diluents, lubricants and glidants.

Suitable diluents may include any conventional diluents, including one or more of microcrystalline cellulose, powdered cellulose, lactose, starch, mannitol, calcium hydrogen phosphate and dextrose.

20 Suitable lubricants may be selected from one or more of talc, magnesium stearate, calcium stearate, polyethylene glycol, hydrogenated vegetable oils, stearic acid, sodium stearyl fumarate and sodium benzoate.

Suitable glidants may be selected from one or more of colloidal silicon dioxide (Aerosil) and talc.

25 The process for manufacturing the pharmaceutical composition includes blending the active ingredient, polymer and optional excipient(s) using one or more of tumbler mixers, ribbon mixers, twin shell V-blenders, double cone blenders, planetary mixers, and fluid bed mixers. The resulting blend is then filled into hard gelatin capsules using either gravity, wherein the powder blend is filled into the capsule due to its natural flow, or
30 partial compression, wherein weak slugs are formed inside a calibrated punch prior to being deposited into the capsule.

Optionally, the lubricants and glidants may be added after thorough blending of other components of the formulation. This blend is passed through a No. 30 mesh screen and filled into capsules, e.g., hard gelatin capsules.

5 The extended release phenytoin sodium capsules maintain a stable dissolution profile after storage for 3 months at 40°C and 75% relative humidity over a two hour period when measured in vitro by dissolution testing. Dissolution testing is carried out in 900 ml of water using USP Dissolution Apparatus I (basket) at 50 rpm (for 100 mg capsules) and 75 rpm (for 200/300 capsules). The 100 mg capsules formulated as described herein show the following in vitro active ingredient dissolution profile: (a) not
10 more than about 35 percent released in about 30 minutes, (b) not more than about 75 percent released in about 60 minutes, and (c) not less than about 65 percent released in about 120 minutes. The 200 mg and 300 mg capsules show the following in vitro dissolution profile: (a) not more than about 40 percent released in about 30 minutes, (b) not more than about 65 percent released in about 60 minutes, and (c) not less than about
15 75 percent released in about 120 minutes.

The extended release capsules of phenytoin sodium described herein provide a method for the control of generalized tonic-clonic (grand mal) seizures and complex partial (psychomotor, temporal lobe) seizures. Additional indications include administering the capsules for the prevention and/or treatment of seizures occurring during
20 or following neurosurgery to a patient in need thereof. Such a method includes administering extended-release pharmaceutical compositions that include a blend of phenytoin sodium and one or more hydrophilic polymers.

The extended-release pharmaceutical composition may also include one or more additional active ingredients combined into a single pharmaceutical composition. Suitable
25 additional active ingredients may include phenobarbitone and pentobarbital.

The following examples further exemplify the invention and are not intended to limit the scope of the invention.

EXAMPLES 1-5

Ingredients	mg/Capsule				
	Ex 1	Ex 2	Ex 3	Ex 4	Ex 5
Phenytoin sodium	300.0	300.0	300.0	300.0	300.0
Xanthan gum	20.0	25.0	20.0	20.0	20.0
Hydroxypropyl cellulose	25.0	35.0	20.0	-	30.0
Hydroxypropyl methylcellulose	75.0	90.0	80.0	100.0	55.0
Microcrystalline cellulose	18.75	18.75	18.75	18.75	18.75
Talc	15.0	15.0	15.0	15.0	15.0
Colloidal silicon dioxide	1.25	1.25	1.25	1.25	1.25
Magnesium stearate	10.0	10.0	10.0	10.0	10.0

Process:

Phenytoin sodium, microcrystalline cellulose, hydroxypropyl cellulose, xanthan gum and hydroxypropyl methylcellulose are loaded into a twin shell V-blender and blended. Talc, colloidal silicon dioxide and magnesium stearate then are added to the blend and mixed. This blend is screened through a No. 30 mesh screen and filled into size "0" hard gelatin capsules using automatic capsule filling machines. These capsules were then packed into high-density polyethylene bottles and stored for 3 months at 40°C and 75% relative humidity and tested for in-vitro dissolution. Table 1 shows the dissolution data of Phenytoin sodium 300 mg capsules prepared as per the composition of Example 3 at the initial time before storage and after storage for 3 months at 40°C and 75% relative humidity.

Table 1: In vitro dissolution profile of Phenytoin sodium capsules using USP Apparatus I/900ml water/75 rpm

Time (min)	Percent phenytoin sodium released (%)	
	Initial	After storage for 3 months at 40°C/ 75% RH
30	20.0	22.0
60	42.0	44.0
120	73.0	79.0

As illustrated in Table 1, the dosage form releases the active ingredient as follows: about 20-30% after 30 minutes, about 40-50% after 60 minutes, and about 75-85% after 120 minutes.

EXAMPLE 6

Ingredients	mg/Capsule
Phenytoin sodium	100.0
Xanthan gum	6.7
Hydroxypropyl cellulose	6.7
Hydroxypropyl methylcellulose	26.7
Microcrystalline cellulose	6.25
Talc	5.0
Colloidal silicon dioxide	0.42
Magnesium stearate	3.33

Process:

Phenytoin sodium, microcrystalline cellulose, hydroxypropyl cellulose, xanthan gum and hydroxypropyl methylcellulose are loaded into a twin shell V-blender and blended. Talc, colloidal silicon dioxide and magnesium stearate are added to the blend and mixed. This blend is screened through a No. 30 mesh screen and filled into size "0" hard gelatin capsules using automatic capsule filling machines. These capsules then are packed into high-density polyethylene bottles and stored for 3 months at 40°C and 75% relative humidity and tested for in-vitro dissolution.

Table 2 shows the dissolution data of Phenytoin sodium 100 mg capsules prepared as per the composition of Example 6 using USP Apparatus I, 900ml water at 50 and 75 RPM.

Table 2: In vitro dissolution profile of Phenytoin sodium capsules using USP Apparatus I/900ml water.

Time (min)	Phenytoin sodium released (%)	
	At 50 RPM	At 75 RPM
30	33.0	45.0
60	71.0	79.0
90	91.0	93.0
120	97.0	95.0

As illustrated in Table 2, at 50 RPM the dosage form releases the active ingredient as follows: about 30-40% after 30 minutes, about 65-75% after 60 minutes, about 87-94% after 90 minutes, and about 93-99% after 120 minutes.

While several particular forms of the invention have been illustrated and described, it will be apparent that various modifications and combinations of the invention detailed in the text can be made without departing from the spirit and scope of the invention. For example, an extended release capsule can be formulated that consists essentially of a
5 simple blend or mixture of phenytoin sodium and one or more hydrophilic polymers, such as those described above. Other nonessential ingredients optionally can be added to the blend or mixture for cosmetic, aesthetic and/or manufacturing purposes. These include colorants, diluents, lubricants, and glidants. Further, it is contemplated that any single feature or any combination of optional features of the inventive variations described herein
10 may be specifically excluded from the claimed invention and be so described as a negative limitation. Accordingly, it is not intended that the invention be limited, except as by the appended claims.